REVMED Co., Ltd. participated in Arab Health 2025, the prominent international medical device exhibition held at the Dubai World Trade Center, United Arab Emirates. Through participation in Arab Health 2025, REVMED aims to broaden partnerships with Middle Eastern countries and accelerate its entry into the global market.
At Arab Health 2025, REVMED showcased its innovative autologous cell isolation and concentration technologies. Leveraging Korea’s advanced regenerative medical technology, REVMED has secured competitiveness in the Middle Eastern and European markets and introduced its technologies at the exhibition.
Additionally, REVMED presented its "TriCell" and "NovaStem" product lines, featuring advanced capabilities in extracting platelets, CD34+ stem cells, T-cells, and immune cells from blood. The company also expanded its product portfolio by unveiling "Rewave," a skin regeneration device utilizing ultrashort-wave technology, and "Brifill," an HA filler. The "Rewave" device, which promotes skin regeneration and collagen production, is expected to support REVMED’s expansion into the Middle Eastern aesthetics market.
REVMED has successfully supplied biological preparation isolation and concentration kits using the "TriCell" system in the Middle Eastern market, strengthening partnerships with local medical institutions. This technology efficiently isolates specific cell layers, including T-cells, lymphocytes, and monocytes, underscoring the technological excellence of Korean biotechnology.
A REVMED representative said, "Through participation in Arab Health 2025, REVMED aims to broaden partnerships in Saudi Arabia, Kuwait, and other countries, setting ambitious revenue growth targets for the Middle Eastern market in 2025. As a leading company in the global biological preparations market, we will continuously innovate and expand into all categories of regenerative medicine.“
Copyright ⓒ 시선뉴스 무단 전재 및 재배포 금지
